Conophylline protects cells in cellular models of neurodegenerative diseases by inducing mammalian target of rapamycin (mTOR)-independent autophagy

J Biol Chem. 2015 Mar 6;290(10):6168-78. doi: 10.1074/jbc.M114.606293. Epub 2015 Jan 16.

Abstract

Macroautophagy is a cellular response that leads to the bulk, nonspecific degradation of cytosolic components, including organelles. In recent years, it has been recognized that autophagy is essential for prevention of neurodegenerative diseases, including Parkinson disease (PD) and Huntington disease (HD). Here, we show that conophylline (CNP), a vinca alkaloid, induces autophagy in an mammalian target of rapamycin-independent manner. Using a cellular model of PD, CNP suppressed protein aggregation and protected cells from cell death caused by treatment with 1-methyl-4-phenylpyridinium, a neurotoxin, by inducing autophagy. Moreover, in the HD model, CNP also eliminated mutant huntingtin aggregates. Our findings demonstrate the possible use of CNP as a therapeutic drug for neurodegenerative disorders, including PD and HD.

Keywords: Aggresome; Autophagy; Conophylline; Huntington Disease; Parkinson Disease; Protein Degradation.

MeSH terms

  • Animals
  • Autophagy / drug effects*
  • COS Cells
  • Chlorocebus aethiops
  • Humans
  • Huntingtin Protein
  • Huntington Disease / drug therapy*
  • Huntington Disease / genetics
  • Huntington Disease / pathology
  • Nerve Tissue Proteins / genetics
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / genetics
  • Parkinson Disease / pathology
  • Protective Agents / administration & dosage
  • Protein Aggregation, Pathological / drug therapy*
  • Protein Aggregation, Pathological / pathology
  • TOR Serine-Threonine Kinases / metabolism
  • Vinca Alkaloids / administration & dosage*

Substances

  • HTT protein, human
  • Huntingtin Protein
  • Nerve Tissue Proteins
  • Protective Agents
  • Vinca Alkaloids
  • conophylline
  • MTOR protein, human
  • TOR Serine-Threonine Kinases